Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and gamma emitter, appropriate for radiotherapy β-energy and with a half-life sui...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-05, Vol.24 (11), p.9154
Main Authors: Krasnovskaya, Olga O., Abramchuck, Daniil, Erofeev, Alexander, Gorelkin, Peter, Kuznetsov, Alexander, Shemukhin, Andrey, Beloglazkina, Elena K.
Format: Article
Language:English
Subjects:
Alzheimer's disease
Biodistribution
Cancer therapies
Chelation
Computed tomography
copper-64
copper-67
Dosimetry
Drug dosages
Emitters
Energy
Isotopes
Medical imaging
Nuclear medicine
Nuclear reactors
PET
Photon emission
Positron emission
Positron emission tomography
Precision medicine
Radiation therapy
radioimmunotherapy
Radioisotopes
radiotherapy
Review
Single photon emission computed tomography
SPECT
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and gamma emitter, appropriate for radiotherapy β-energy and with a half-life suitable for single-photon emission computed tomography (SPECT) imaging. The chemical identities of 64Cu and 67Cu isotopes allow for convenient use of the same chelating molecules for sequential PET imaging and radiotherapy. A recent breakthrough in 67Cu production opened previously unavailable opportunities for a reliable source of 67Cu with high specific activity and purity. These new opportunities have reignited interest in the use of copper-containing radiopharmaceuticals for the therapy, diagnosis, and theranostics of various diseases. Herein, we summarize recent (2018–2023) advances in the use of copper-based radiopharmaceuticals for PET, SPECT imaging, radiotherapy, and radioimmunotherapy.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24119154